Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Capital Employed (2019 - 2025)

Cyclerion Therapeutics has reported Return on Capital Employed over the past 7 years, most recently at 0.4% for Q3 2025.

  • Quarterly results put Return on Capital Employed at 0.4% for Q3 2025, up 27.0% from a year ago — trailing twelve months through Sep 2025 was 0.4% (up 27.0% YoY), and the annual figure for FY2024 was 0.34%, up 61.0%.
  • Return on Capital Employed for Q3 2025 was 0.4% at Cyclerion Therapeutics, up from 0.43% in the prior quarter.
  • Over the last five years, Return on Capital Employed for CYCN hit a ceiling of 0.4% in Q1 2025 and a floor of 3.55% in Q1 2023.
  • Median Return on Capital Employed over the past 5 years was 1.05% (2021), compared with a mean of 1.28%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -229bps in 2023 and later surged 252bps in 2024.
  • Cyclerion Therapeutics' Return on Capital Employed stood at 1.05% in 2021, then tumbled by -141bps to 2.54% in 2022, then skyrocketed by 58bps to 1.06% in 2023, then soared by 60bps to 0.43% in 2024, then increased by 5bps to 0.4% in 2025.
  • The last three reported values for Return on Capital Employed were 0.4% (Q3 2025), 0.43% (Q2 2025), and 0.4% (Q1 2025) per Business Quant data.